MindMed Files Preliminary Prospectus In Connection With Bought Deal Equity Financing


TORONTO, Oct. 16, 2020 /CNW/ — Mind Medicine (MindMed) Inc. (NEO: MMED) (OTCQB: MMEDF) (“MindMed” or a “Company“) is gratified to announce that serve to a formerly announced charity (the “Offering“) on October 9, 2020, it has filed a rough brief form handbill (the “Preliminary Prospectus“) with a bonds commissions or identical authorities in any range of Canada, other than Québec. Pursuant to a underwriting agreement with Canaccord Genuity Corp. (the “Underwriter“), a Underwriter has concluded to squeeze 23,810,000 units of a Company (the “Units“), on a “bought deal” basis, during a cost per Unit of CAD$1.05 (the “Issue Price“) for sum deduction of CAD$25,000,500.

Mindmed trademark (PRNewsfoto/Mind Medicine, Inc. (Mindmed))Mindmed trademark (PRNewsfoto/Mind Medicine, Inc. (Mindmed))

The Company has also postulated a Underwriter an over-allotment choice to squeeze adult to an additional 15% of a Units during a Issue Price, exercisable in whole or in part, during any time on or before to a date that is 30 days following a shutting of a Offering. If this choice is exercised in full, an additional CAD$3,750,075 will be lifted pursuant to a Offering and a total deduction of a Offering will be approximately CAD$28,750,575.

Each Unit will be comprised of one subordinate voting share of a Company (a “Subordinate Voting Share“) and one-half of one Subordinate Voting Share squeeze aver (each whole warrant, a “Warrant“). Each Warrant shall grant a hilt thereof to squeeze one Subordinate Voting Share during an practice cost of CAD$1.40, for a duration of 36 months following a shutting of a Offering.

The Company intends to use a net deduction of a Offering for investment in a investigate and clinical growth initiatives, including a 18-MC program, lysergic poison diethylamide (LSD) microdosing program, LSD experiential therapy for stress research, University Hospital Basel Liechti Lab partnership and NYU Langone Health program, and for ubiquitous operative collateral and corporate purposes.

The Offering is scheduled to tighten on or about October 30, 2020 and is theme to certain conditions including, though not singular to, a receipt of all compulsory approvals, including a capitulation of a Neo Exchange Inc. and a germane bonds regulatory authorities.

This press recover shall not consecrate an offer to sell or a questionnaire of an offer to buy nor shall there be any sale of a bonds in any state in that such offer, questionnaire or sale would be unlawful. The bonds being offering have not been, nor will they be, purebred underneath the United States Securities Act of 1933, as amended, and might not be offering or sole in the United States absent registration or an germane grant from a registration mandate of the United States Securities Act of 1933, as amended, and germane state bonds laws.

The Preliminary Prospectus containing critical information relating to these bonds has been filed with bonds commissions or identical authorities in any range of Canada, other than Québec. The Preliminary Prospectus is still theme to execution or amendment. A duplicate of a Preliminary Prospectus can be performed underneath a Company’s corporate form on SEDAR during www.sedar.com. There will not be any sale or any acceptance of an offer to buy a bonds until a receipt for a final brief form handbill has been issued.

About MindMed

MindMed is a unusual medicine biotech association that discovers, develops and deploys unusual desirous medicines and therapies to residence obsession and mental illness. The association is convention a constrained drug growth tube of innovative treatments formed on unusual substances including Psilocybin, LSD, MDMA, DMT and an Ibogaine derivative, MC-18. The MindMed executive group brings endless biopharmaceutical knowledge to a Company’s groundbreaking proceed to building a successive era of unusual desirous medicines and therapies.

MindMed trades on a Canadian sell NEO underneath a pitch MMED. MindMed is also traded in the United States underneath a pitch MMEDF and in Germany underneath a pitch MMQ. For some-more information: http://www.mindmed.co/.

Forward-Looking Statements

Certain statements in this news recover associated to a Company are forward-looking statements and are impending in nature. Forward-looking statements are not formed on chronological facts, though rather on stream expectations and projections about destiny events and are therefore theme to risks and uncertainties that could means tangible formula to differ materially from a destiny formula voiced or pragmatic by a forward-looking statements. These statements generally can be identified by a use of forward-looking difference such as “may”, “should”, “could”, “intend”, “estimate”, “plan”, “anticipate”, “expect”, “believe” or “continue”, or a disastrous thereof or identical variations. Forward-looking statements in this news recover embody statements per a shutting of a Offering, regulatory approvals and a dictated use of deduction of a Offering. There are countless risks and uncertainties that could means tangible formula and MindMed’s skeleton and objectives to differ materially from those voiced in a forward-looking information. Actual formula and destiny events could differ materially from those expected in such information. These and all successive created and verbal forward-looking information are formed on estimates and opinions of government on a dates they are done and are specifically competent in their entirety by this notice. Except as compulsory by law, a Company does not intend to refurbish these forward-looking statements.

Media Contact: mindmed@crosscutstrategies.com

Investor Relations: invest@mindmed.co

SOURCE Mind Medicine (MindMed) Inc.


View strange calm to download multimedia: http://www.newswire.ca/en/releases/archive/October2020/16/c7190.html

You must be logged in to post a comment Login

Widgetized Section

Go to Admin » appearance » Widgets » and move a widget into Advertise Widget Zone